Single Nucleotide Polymorphisms In Patients With Advanced Gastric Cancer. Xrcc1g399a Oxaliplatin Chemotherapy Sensitivity

OBJECTIVE:To examine the association between genetic polymorphisms of XRCC1 Arg399GIn(Gâ†'A) and response to oxaliplatin-based chemotherapy of advanced gastric cancer.METHODS:TotalIy 94 patients (34 stageâ…¢,60 stageâ…£) with advanced gastric cancer were treated with oxaliplatin-based chemotherapy,and clinical response of all the patients were evaluated after 2 to 3 cycles.Also the 94 patients were evaluated time to progression (TTP). DNA were extracted from peripheral blood before chemotherapy. XRCC1 genotypes were detected by TaqMan-MGB probe methods. RESULTS:54.26% were G/G genotype,8.5% were A/A genotype,and 37.24% were G/A genotype.The clinical benefit rate (CR+PR+SD) was 62%. Patients with G/G genotype showed distinctly preponderance compared to those with G/A+A/A, between response group(CR+PR+SD) and un-response group (SD) (x2=7.739,p=0.006;OR=3.238,95%CI=2.169-4.835, P<0.01).The median TTP of all patients was 6.3 months; G/G genotype was 7.1 months; G/A and A/A was 5.3 months.There was a significant difference between them (x2=50.55,p<0.01).CONCLUSION:The results suggest that the XRCC1 Arg399Gln genetic polymorphisms may be associated with clinical outcomes of Chinese patients with advanced gastricl cancer accepted Oxaliplatin as first-line treatment.